By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

Key Statistics

Ownership: Public

Web Site: Emergent BioSolutions
Symbol: EBS

Company News
Emergent BioSolutions (EBS) Awarded $29 Million Contract To Develop A Dry Formulation Of Nuthrax 9/9/2014 11:02:37 AM
Emergent BioSolutions (EBS) Awarded Contract To Develop A Dry Formulation Of Nuthrax, A Next Generation Anthrax Vaccine 9/8/2014 12:35:37 PM
Emergent BioSolutions (EBS), MorphoSys AG Strike Prostate Cancer Pact Worth $183 Million 8/20/2014 6:14:28 AM
U.S. Government Exercises Contract Options Valued At $18.9 Million For Emergent BioSolutions (EBS)' Vaccinia Immune Globulin Intravenous Program 8/8/2014 9:45:15 AM
Emergent BioSolutions (EBS) Reports Financial Results For Second Quarter And First Six Months Of 2014 8/8/2014 9:10:30 AM
Emergent BioSolutions (EBS) Submits Biologics License Application To FDA For Anthrax Immune Globulin Intravenous (Human) 8/7/2014 10:04:54 AM
Emergent BioSolutions (EBS) To Participate In June 2014 Investor Conferences 5/29/2014 7:37:02 AM
Emergent BioSolutions (EBS) To Hold Annual Meeting Of Stockholders Thursday May 22, 2014 At 9:00 AM Eastern; Webcast Will Be Available 5/15/2014 9:42:22 AM
Emergent BioSolutions (EBS) Reports First Quarter 2014 Financial Results 5/9/2014 7:25:30 AM
Emergent BioSolutions (EBS) To Release First Quarter 2014 Financial Results And Conduct A Conference Call On May 8, 2014 4/23/2014 7:14:13 AM